These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36723437)

  • 1. CRM197-conjugated peptides vaccine of HCMV pp65 and gH induce maturation of DC and effective viral-specific T cell responses.
    Zhang S; Nan F; Jiang S; Zhou X; Niu D; Li J; Wang H; Zhang X; Zhang X; Wang B
    Virulence; 2023 Dec; 14(1):2169488. PubMed ID: 36723437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development.
    Jiang S; Nan F; Zhang S; Zhang X; Li Z; Yu Z; Liu F; Li J; Zhou X; Niu D; Wang H; Zhang X; Liu W; Yang X; Wang Y; Wang B
    Int J Biol Macromol; 2023 Jan; 224():79-93. PubMed ID: 36252620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.
    Kiener R; Fleischmann M; Wiegand MA; Lemmermann NAW; Schwegler C; Kaufmann C; Renzaho A; Thomas S; Felder E; Niller HH; Asbach B; Wagner R
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29769344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
    Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
    Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).
    Yue Y; Kaur A; Zhou SS; Barry PA
    J Gen Virol; 2006 Apr; 87(Pt 4):777-787. PubMed ID: 16528025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients.
    Lilleri D; Zelini P; Fornara C; Comolli G; Gerna G
    Am J Transplant; 2007 Aug; 7(8):1997-2005. PubMed ID: 17617865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
    Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
    J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens.
    Tabi Z; Moutaftsi M; Borysiewicz LK
    J Immunol; 2001 May; 166(9):5695-703. PubMed ID: 11313411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
    Selinsky C; Luke C; Wloch M; Geall A; Hermanson G; Kaslow D; Evans T
    Hum Vaccin; 2005; 1(1):16-23. PubMed ID: 17038834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
    Gonczol E; Plotkin S
    Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Induction of T Cell Immunity Using Dendritic Cells Pulsed with HIV Tat and HCMV-pp65 Fusion Protein In Vitro.
    Park JS; Park SY; Cho HI; Sohn HJ; Kim TG
    Immune Netw; 2011 Jun; 11(3):182-9. PubMed ID: 21860612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells.
    Arrode G; Boccaccio C; Abastado JP; Davrinche C
    J Virol; 2002 Jan; 76(1):142-50. PubMed ID: 11739680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
    Gerna G; Lilleri D
    New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple and efficient method of generating HCMV pp65-specific T cells using overlapping peptides.
    Hwang SU; Lee JH; Choi SY; Lee YT; Park SY; Lee HS; Jae JW; Jung NC; Wang Y; Lim DS
    Acta Virol; 2020; 64(4):470-479. PubMed ID: 33151741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [VP22 enhances the immunological activity of human cytomegalovirus pp65 DNA vaccine: experimental study with mice].
    Ma DX; Yu XP; Zhang XM; Zhou YB; Li Y; Jia JH; Zhao WM
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1049-52. PubMed ID: 16029549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.
    Lehmann C; Falk JJ; Büscher N; Penner I; Zimmermann C; Gogesch P; Sinzger C; Plachter B
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.
    Diamond DJ; York J; Sun JY; Wright CL; Forman SJ
    Blood; 1997 Sep; 90(5):1751-67. PubMed ID: 9292508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.